Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases.

Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy.

JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026.

The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.